Syntara Limited has released a press release.
Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
- PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial
- Pharmaxis Treatment to Prevent Wound and Burns Scars Clears
- PXS Grants Exclusive Option to Develop High Payload Inhaler
- PXS Drug Decreases Tumour Burden in Liver Cancer Model
Later from Syntara
- FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study
- Security Purchase Plan
- Share Purchase Plan
- PXS Collaborators Receive Government Grants of $1.4m
- Response to ASX Aware Query
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara